Cardica Inc. (CRDC) 2.35 $CRDC
Cardica Changes Company Name to Dextera Surgical
GlobeNewswire - Mon Jun 20, 8:00AM CDT
Cardica, Inc. (Nasdaq:CRDC), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that the company has changed its name to Dextera Surgical Inc. The company's Nasdaq ticker symbol also will be changing, with its common stock to begin trading under the new ticker symbol "DXTR," effective Wednesday, June 22.
CRDC: 2.35 (-0.15)
Cardica Announces Positive Results of Long-Term Evaluation of Company's C-Port(R) System for Vein Grafts in CABG Procedures
GlobeNewswire - Tue May 17, 11:00AM CDT
Positive results of a clinical study of the C-Port Distal Anastomosis System from Cardica, Inc. (Nasdaq:CRDC) were presented today at the Annual Meeting of the American Association for Thoracic Surgery (AATS) by Husam Balkhy, M.D., associate professor of Surgery and director of Robotic and Minimally Invasive Cardiac Surgery at The University of Chicago's Medicine & Biological Sciences Division.
CRDC: 2.35 (-0.15)
Husam Balkhy, M.D. to Present Clinical Study Results of Cardica's C-Port(R) Distal Anastomosis System at the Annual Meeting of American Association for Thoracic Surgery
GlobeNewswire - Wed May 11, 12:00PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced that the results of a clinical study of the C-Port Distal Anastomosis System will be presented at the Annual Meeting of the American Association for Thoracic Surgery (AATS) in Baltimore, Maryland by Husam Balkhy, M.D., associate professor of Surgery and director of Robotic and Minimally Invasive Cardiac Surgery at The University of Chicago's Medicine & Biological Sciences Division. Dr. Balkhy's presentation is scheduled to take place on May 17, 2016 at 7 a.m. ET.
CRDC: 2.35 (-0.15)
Cardica Reports Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Thu May 05, 3:06PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced financial results for its fiscal third quarter ended March 31, 2016. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.73 (+0.07), CSII: 24.34 (-0.13), BAX: 46.05 (-0.68), CRDC: 2.35 (-0.15)
3 Medical Devices Stocks Set to Beat this Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed May 04, 4:02PM CDT
The stupendous first-quarter performance by the Medical sector is something investors definitely need to muse on.
BDX: 176.06 (-1.15), CRDC: 2.35 (-0.15), QSII: 11.64 (-0.13)
Is a Surprise Coming for Cardica (CRDC) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Cardica (CRDC) an interesting choice for the investors.
CRDC: 2.35 (-0.15)
Becton, Dickinson (BDX): Stock Set to Top Earnings in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 2:11PM CDT
Becton, Dickinson and Company (BDX) is expected to report second-quarter fiscal 2016 results on May 5.
BDX: 176.06 (-1.15), CRDC: 2.35 (-0.15), ADAP: 6.41 (-0.29), PRAH: 49.73 (-0.82)
Can Weight Watchers (WTW) Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:15AM CDT
Weight Watchers International Inc. (WTW) is scheduled to release first-quarter 2016 results on May 4.
CRDC: 2.35 (-0.15), ADAP: 6.41 (-0.29), PRAH: 49.73 (-0.82), WTW: 10.30 (-0.21)
Cardica to Announce Fiscal 2016 Third Quarter Financial Results on Thursday, May 5, 2016
GlobeNewswire - Mon Apr 25, 3:05PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced that it will release financial results for its fiscal third quarter ended March 31, 2016, on Thursday, May 5, 2016, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Cardica to Present at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference in New York on February 10th
GlobeNewswire - Thu Feb 04, 3:10PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that Julian Nikolchev, the company's president and CEO, with give a corporate overview and update at Source Capital's 2016 Disruptive Growth and Healthcare Conference on Wednesday, February 10, 2016 at 4:00pm Eastern Time in New York City.
CRDC: 2.35 (-0.15)
Cardica Reports Fiscal 2016 Second Quarter Financial Results and Business Progress
GlobeNewswire - Thu Feb 04, 3:08PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced financial results for its fiscal second quarter ended December 31, 2015. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Global Cardiovascular Prosthetic Devices Pipeline Assessment 2015-2016
M2 - Tue Feb 02, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/j7tzls/cardiovascular) has announced the addition of the "Cardiovascular Prosthetic Devices - Medical Devices Pipeline Assessment, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiovascular Prosthetic Devices pipeline products. Scope - Extensive coverage of the Cardiovascular Prosthetic Devices under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Cardiovascular Prosthetic Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Cardiovascular Prosthetic Devices - Pipeline Products under Development by Companies 5 Cardiovascular Prosthetic Devices Companies and Product Overview 6 Cardiovascular Prosthetic Devices- Recent Developments 7 Appendix Companies Mentioned - 4tech Cardio Ireland Limited - Agamit Medical Ltd. - Ample Medical Inc. - Amsel Medical Corporation - Aporo Biomedical, Inc. - Arbor Surgical Technologies, Inc. - BioStable Science & Engineering, Inc. - BioVentrix, Inc. - CARAG AG - Cardica, Inc. - Cardiosolutions, Inc. For more information visit http://www.researchandmarkets.com/research/j7...iovascular
CRDC: 2.35 (-0.15)
Global Surgical Devices Medical Pipeline Assessment 2015-2016
M2 - Tue Feb 02, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/hnr9fb/surgical_devices) has announced the addition of the "Surgical Devices - Medical Devices Pipeline Assessment, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Surgical Devices pipeline products. Scope - Extensive coverage of the Surgical Devices under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Surgical Devices - Pipeline Products under Development by Companies 5 Surgical Devices Companies and Product Overview 6 Surgical Devices- Recent Developments 7 Appendix Companies Mentioned (Partial List) - Adept Medical Limited - Anastom Surgical - Apollo Endosurgery, Inc. - Applied Medical Resources Corporation - Arkis BioSciences - Bio DG - BioTex, Inc. - Boston Scientific Corporation - BriteSeed - C. R. Bard, Inc. - Cardica, Inc. - Carnegie Mellon University - CarpoNovum AB - Castle Surgical, Inc. - CIVCO Medical Solutions - Cologuard Ltd - Control Medical Technology, LLC - Core Essence Orthopaedics, LLC - Cytori Therapeutics, Inc. - Ding Hwa Co., Ltd - Embricon Limited - EndoEvolution, LLC - Ethicon Endo-Surgery, Inc. - Eximo Medical Ltd. - Medisse BV - Medivur - Medtronic plc - Parker Hannifin Corporation - Physcient, Inc. - POP Medical Solutions - Pro-Dex, Inc. - Queen Mary University of London - Ratner BioMedical Inc. - Resultados y Calidad del Sistema Sanitario Publico de Andalucia - Sanovas, Inc. For more information visit http://www.researchandmarkets.com/research/hn...al_devices
BSX: 23.98 (+0.16), MDT: 86.72 (-0.31), CYTX: 2.02 (-0.01), CRDC: 2.35 (-0.15)
Innovative Cardica Technology for Microlobectomy Procedures Featured in Presentation at STS/AATS Tech-Con 2016
GlobeNewswire - Mon Jan 25, 3:09PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that the company's MicroCutter XCHANGE 30, the world's first and only five-millimeter surgical stapler with the capability to articulate 80 degrees, was featured in a "Lung Surgery of the Future" presentation by Joel Dunning, M.D., cardiothoracic surgeon at James Cook University Hospital, Department of Cardiothoracic Surgery in Middlesbrough, U.K., at The Society of Thoracic Surgeons and American Association for Thoracic Surgery's Tech Conference (STS/AATS Tech-Con) on Saturday in Phoenix, Ariz.
CRDC: 2.35 (-0.15)
Cardica to Announce Fiscal 2016 Second Quarter Financial Results on Thursday, February 4, 2016
GlobeNewswire - Mon Jan 25, 3:09PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that it will release financial results for its fiscal second quarter ended December 31, 2015, on Thursday, February 4, 2016, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Procedure Enabled by Innovative Cardica Technology to be Featured at STS/AATS Tech-Con 2016
GlobeNewswire - Thu Jan 21, 3:34PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced the company's MicroCutter XCHANGE(R) 30 surgical stapler, with a shaft diameter of 5 millimeters and the capability to articulate 80 degrees, will be featured in a presentation describing a cutting-edge lobectomy technique at The Society of Thoracic Surgeons and American Association for Thoracic Surgery's Tech Conference (Tech-Con) to be held January 23-24 in Phoenix, Ariz.
CRDC: 2.35 (-0.15)
Cardica Receives FDA Clearance for Multiple Expanded Indications of World's Smallest-Profile Articulating Surgical Stapling Device
GlobeNewswire - Tue Jan 19, 7:09AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to use its MicroCutter XCHANGE 30 surgical stapling device with a white cartridge for the transection and resection in open or minimally invasive urologic, thoracic, and pediatric surgical procedures. This clearance complements the existing indications for use of the MicroCutter XCHANGE 30 in surgical procedures in the small and large intestine and in the appendix.
CRDC: 2.35 (-0.15)
Cardica and Intuitive Surgical Amend License Agreement
GlobeNewswire - Thu Jan 07, 7:00AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that the company has amended its license agreement, initially signed in August 2010, with Intuitive Surgical, Inc. (Nasdaq:ISRG) to include an agreement providing for the evaluation and potential development of a surgical stapling cartridge for use with Intuitive Surgical's da Vinci Surgical Systems.
ISRG: 685.60 (-0.82), CRDC: 2.35 (-0.15)
Cardica Submits Additional Documentation to FDA in Support of 510(k) Submission
GlobeNewswire - Wed Dec 16, 7:00AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that it submitted its responses to the questions raised by the U.S. Food and Drug Administration (FDA) on Cardica's 510(k) submission for an expanded Indication for Use for the MicroCutter XCHANGE(R) 30. The responses to the FDA included the results from Cardica's new chronic animal study conducted specifically in response to one of the FDA's questions.
CRDC: 2.35 (-0.15)
Cardica Changes Company Name to Dextera Surgical
GlobeNewswire - Mon Jun 20, 8:00AM CDT
Cardica, Inc. (Nasdaq:CRDC), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that the company has changed its name to Dextera Surgical Inc. The company's Nasdaq ticker symbol also will be changing, with its common stock to begin trading under the new ticker symbol "DXTR," effective Wednesday, June 22.
CRDC: 2.35 (-0.15)
Cardica Announces Positive Results of Long-Term Evaluation of Company's C-Port(R) System for Vein Grafts in CABG Procedures
GlobeNewswire - Tue May 17, 11:00AM CDT
Positive results of a clinical study of the C-Port Distal Anastomosis System from Cardica, Inc. (Nasdaq:CRDC) were presented today at the Annual Meeting of the American Association for Thoracic Surgery (AATS) by Husam Balkhy, M.D., associate professor of Surgery and director of Robotic and Minimally Invasive Cardiac Surgery at The University of Chicago's Medicine & Biological Sciences Division.
CRDC: 2.35 (-0.15)
Husam Balkhy, M.D. to Present Clinical Study Results of Cardica's C-Port(R) Distal Anastomosis System at the Annual Meeting of American Association for Thoracic Surgery
GlobeNewswire - Wed May 11, 12:00PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced that the results of a clinical study of the C-Port Distal Anastomosis System will be presented at the Annual Meeting of the American Association for Thoracic Surgery (AATS) in Baltimore, Maryland by Husam Balkhy, M.D., associate professor of Surgery and director of Robotic and Minimally Invasive Cardiac Surgery at The University of Chicago's Medicine & Biological Sciences Division. Dr. Balkhy's presentation is scheduled to take place on May 17, 2016 at 7 a.m. ET.
CRDC: 2.35 (-0.15)
Cardica Reports Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Thu May 05, 3:06PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced financial results for its fiscal third quarter ended March 31, 2016. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.73 (+0.07), CSII: 24.34 (-0.13), BAX: 46.05 (-0.68), CRDC: 2.35 (-0.15)
3 Medical Devices Stocks Set to Beat this Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed May 04, 4:02PM CDT
The stupendous first-quarter performance by the Medical sector is something investors definitely need to muse on.
BDX: 176.06 (-1.15), CRDC: 2.35 (-0.15), QSII: 11.64 (-0.13)
Is a Surprise Coming for Cardica (CRDC) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Cardica (CRDC) an interesting choice for the investors.
CRDC: 2.35 (-0.15)
Becton, Dickinson (BDX): Stock Set to Top Earnings in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 2:11PM CDT
Becton, Dickinson and Company (BDX) is expected to report second-quarter fiscal 2016 results on May 5.
BDX: 176.06 (-1.15), CRDC: 2.35 (-0.15), ADAP: 6.41 (-0.29), PRAH: 49.73 (-0.82)
Can Weight Watchers (WTW) Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:15AM CDT
Weight Watchers International Inc. (WTW) is scheduled to release first-quarter 2016 results on May 4.
CRDC: 2.35 (-0.15), ADAP: 6.41 (-0.29), PRAH: 49.73 (-0.82), WTW: 10.30 (-0.21)
Cardica to Announce Fiscal 2016 Third Quarter Financial Results on Thursday, May 5, 2016
GlobeNewswire - Mon Apr 25, 3:05PM CDT
Cardica, Inc. (Nasdaq:CRDC) today announced that it will release financial results for its fiscal third quarter ended March 31, 2016, on Thursday, May 5, 2016, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Cardica to Present at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference in New York on February 10th
GlobeNewswire - Thu Feb 04, 3:10PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that Julian Nikolchev, the company's president and CEO, with give a corporate overview and update at Source Capital's 2016 Disruptive Growth and Healthcare Conference on Wednesday, February 10, 2016 at 4:00pm Eastern Time in New York City.
CRDC: 2.35 (-0.15)
Cardica Reports Fiscal 2016 Second Quarter Financial Results and Business Progress
GlobeNewswire - Thu Feb 04, 3:08PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced financial results for its fiscal second quarter ended December 31, 2015. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Global Cardiovascular Prosthetic Devices Pipeline Assessment 2015-2016
M2 - Tue Feb 02, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/j7tzls/cardiovascular) has announced the addition of the "Cardiovascular Prosthetic Devices - Medical Devices Pipeline Assessment, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiovascular Prosthetic Devices pipeline products. Scope - Extensive coverage of the Cardiovascular Prosthetic Devices under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Cardiovascular Prosthetic Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Cardiovascular Prosthetic Devices - Pipeline Products under Development by Companies 5 Cardiovascular Prosthetic Devices Companies and Product Overview 6 Cardiovascular Prosthetic Devices- Recent Developments 7 Appendix Companies Mentioned - 4tech Cardio Ireland Limited - Agamit Medical Ltd. - Ample Medical Inc. - Amsel Medical Corporation - Aporo Biomedical, Inc. - Arbor Surgical Technologies, Inc. - BioStable Science & Engineering, Inc. - BioVentrix, Inc. - CARAG AG - Cardica, Inc. - Cardiosolutions, Inc. For more information visit http://www.researchandmarkets.com/research/j7...iovascular
CRDC: 2.35 (-0.15)
Global Surgical Devices Medical Pipeline Assessment 2015-2016
M2 - Tue Feb 02, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/hnr9fb/surgical_devices) has announced the addition of the "Surgical Devices - Medical Devices Pipeline Assessment, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Surgical Devices pipeline products. Scope - Extensive coverage of the Surgical Devices under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Surgical Devices - Pipeline Products under Development by Companies 5 Surgical Devices Companies and Product Overview 6 Surgical Devices- Recent Developments 7 Appendix Companies Mentioned (Partial List) - Adept Medical Limited - Anastom Surgical - Apollo Endosurgery, Inc. - Applied Medical Resources Corporation - Arkis BioSciences - Bio DG - BioTex, Inc. - Boston Scientific Corporation - BriteSeed - C. R. Bard, Inc. - Cardica, Inc. - Carnegie Mellon University - CarpoNovum AB - Castle Surgical, Inc. - CIVCO Medical Solutions - Cologuard Ltd - Control Medical Technology, LLC - Core Essence Orthopaedics, LLC - Cytori Therapeutics, Inc. - Ding Hwa Co., Ltd - Embricon Limited - EndoEvolution, LLC - Ethicon Endo-Surgery, Inc. - Eximo Medical Ltd. - Medisse BV - Medivur - Medtronic plc - Parker Hannifin Corporation - Physcient, Inc. - POP Medical Solutions - Pro-Dex, Inc. - Queen Mary University of London - Ratner BioMedical Inc. - Resultados y Calidad del Sistema Sanitario Publico de Andalucia - Sanovas, Inc. For more information visit http://www.researchandmarkets.com/research/hn...al_devices
BSX: 23.98 (+0.16), MDT: 86.72 (-0.31), CYTX: 2.02 (-0.01), CRDC: 2.35 (-0.15)
Innovative Cardica Technology for Microlobectomy Procedures Featured in Presentation at STS/AATS Tech-Con 2016
GlobeNewswire - Mon Jan 25, 3:09PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that the company's MicroCutter XCHANGE 30, the world's first and only five-millimeter surgical stapler with the capability to articulate 80 degrees, was featured in a "Lung Surgery of the Future" presentation by Joel Dunning, M.D., cardiothoracic surgeon at James Cook University Hospital, Department of Cardiothoracic Surgery in Middlesbrough, U.K., at The Society of Thoracic Surgeons and American Association for Thoracic Surgery's Tech Conference (STS/AATS Tech-Con) on Saturday in Phoenix, Ariz.
CRDC: 2.35 (-0.15)
Cardica to Announce Fiscal 2016 Second Quarter Financial Results on Thursday, February 4, 2016
GlobeNewswire - Mon Jan 25, 3:09PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that it will release financial results for its fiscal second quarter ended December 31, 2015, on Thursday, February 4, 2016, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
CRDC: 2.35 (-0.15)
Procedure Enabled by Innovative Cardica Technology to be Featured at STS/AATS Tech-Con 2016
GlobeNewswire - Thu Jan 21, 3:34PM CST
Cardica, Inc. (Nasdaq:CRDC) today announced the company's MicroCutter XCHANGE(R) 30 surgical stapler, with a shaft diameter of 5 millimeters and the capability to articulate 80 degrees, will be featured in a presentation describing a cutting-edge lobectomy technique at The Society of Thoracic Surgeons and American Association for Thoracic Surgery's Tech Conference (Tech-Con) to be held January 23-24 in Phoenix, Ariz.
CRDC: 2.35 (-0.15)
Cardica Receives FDA Clearance for Multiple Expanded Indications of World's Smallest-Profile Articulating Surgical Stapling Device
GlobeNewswire - Tue Jan 19, 7:09AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to use its MicroCutter XCHANGE 30 surgical stapling device with a white cartridge for the transection and resection in open or minimally invasive urologic, thoracic, and pediatric surgical procedures. This clearance complements the existing indications for use of the MicroCutter XCHANGE 30 in surgical procedures in the small and large intestine and in the appendix.
CRDC: 2.35 (-0.15)
Cardica and Intuitive Surgical Amend License Agreement
GlobeNewswire - Thu Jan 07, 7:00AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that the company has amended its license agreement, initially signed in August 2010, with Intuitive Surgical, Inc. (Nasdaq:ISRG) to include an agreement providing for the evaluation and potential development of a surgical stapling cartridge for use with Intuitive Surgical's da Vinci Surgical Systems.
ISRG: 685.60 (-0.82), CRDC: 2.35 (-0.15)
Cardica Submits Additional Documentation to FDA in Support of 510(k) Submission
GlobeNewswire - Wed Dec 16, 7:00AM CST
Cardica, Inc. (Nasdaq:CRDC) today announced that it submitted its responses to the questions raised by the U.S. Food and Drug Administration (FDA) on Cardica's 510(k) submission for an expanded Indication for Use for the MicroCutter XCHANGE(R) 30. The responses to the FDA included the results from Cardica's new chronic animal study conducted specifically in response to one of the FDA's questions.
CRDC: 2.35 (-0.15)
